530P Phase II study of PI3K inhibitor copanlisib in cancer patients with deleterious PTEN mutations and retained PTEN protein expression: Results from the NCI-MATCH Trial (EAY131) sub-protocol Z1H
| Autor: | Janku, F., Wei, Z., Davies, M.A., Mitchell, E.P., Wright, J.J., Doyle, L.A., Gray, R.J., Wang, V., McShane, L.M., Rubinstein, L.V., Patton, D.R., Williams, P.M., Hamilton, S.R., Conley, B., Arteaga, C.L., Harris, L.N., O'Dwyer, P.J., Chen, A.P., Flaherty, K.T. |
|---|---|
| Zdroj: | In Annals of Oncology September 2021 32 Supplement 5:S595-S596 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|